Veterinary Biomarkers Market (2026 - 2033)

Veterinary Biomarkers Market Summary

The global veterinary biomarkers market size was valued at USD 1.1 billion in 2025 and is projected to grow from USD 1.2 billion in 2026 to USD 2.6 billion by 2033, at a CAGR of 12.1% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 33.0% in 2025. The increasing prevalence of chronic conditions such as cancer and cardiovascular diseases in animals is significantly increasing the demand for biomarker-based assay diagnostic kits in veterinary applications to predict disease in its early stages.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The R&D activities implemented by key companies to enhance biomarker portfolios are fueling market growth.

To learn more about this report, Download Free Sample Report

Market Dynamics

The veterinary biomarkers industry is witnessing significant growth, driven by the rising prevalence of chronic and infectious diseases in companion and production animals, increasing pet humanization, and higher spending on animal healthcare. Pet owners are becoming more proactive in seeking preventive care, routine health screening, and early disease diagnosis, leading to greater adoption of biomarker-based diagnostic tests. The growing emphasis on precision veterinary medicine is further accelerating demand for biomarkers that enable early disease detection, disease monitoring, and personalized treatment strategies, ultimately improving clinical outcomes and quality of animal care.

In addition, increasing expenditure on pet healthcare is creating favorable conditions for the adoption of advanced veterinary diagnostics. According to the American Pet Products Association (APPA), U.S. pet industry expenditures reached USD 158 billion in 2025 and are projected to increase to USD 165 billion in 2026, while pet ownership remained strong with 95 million U.S. households owning at least one pet. Rising investments by pet owners in preventive healthcare, diagnostics, and specialized veterinary services are encouraging veterinary clinics and diagnostic laboratories to adopt biomarker-based testing solutions. Coupled with continuous advancements in molecular diagnostics and growing investments in biomarker research by key industry players, these trends are expected to support the sustained growth of the veterinary biomarkers market.

Market Characteristics & Concentration

The veterinary biomarkers industry is moderately consolidated, with a mix of established animal health companies and specialized diagnostic firms competing through innovation and product development. Market participants are continuously investing in research and development, strategic collaborations, and technological advancements to improve biomarker accuracy, broaden diagnostic applications, and strengthen their product portfolios, thereby supporting the overall growth of the sector.

The veterinary biomarkers industry is characterized by a high level of innovation, driven by continuous advances in molecular diagnostics, genomics, proteomics, metabolomics, and precision veterinary medicine. Companies are developing novel biomarkers that enable earlier disease detection, improve disease monitoring, and support personalized treatment decisions across companion and production animals.

To learn more about this report, Download Free Sample Report

The veterinary biomarkers industry has witnessed a moderate level of mergers, acquisitions, and strategic collaborations as companies seek to strengthen their biomarker discovery capabilities and expand their diagnostic portfolios. Established animal health companies are partnering with biotechnology firms, research organizations, and diagnostic laboratories to accelerate product development and commercialize new biomarker-based technologies. These collaborations also help companies gain access to advanced research platforms, expand their geographic presence, and enhance their competitive position within the veterinary diagnostics industry.

Regulations play a significant role in shaping the veterinary biomarkers sector by ensuring the safety, quality, and reliability of diagnostic products. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national authorities establish guidelines for the development, validation, and commercialization of veterinary diagnostic tests. Compliance with these standards is essential for product approval and commercialization. Although regulatory requirements can increase development timelines and costs, they also strengthen confidence among veterinarians and animal health professionals regarding the accuracy and clinical value of biomarker-based diagnostics.

The veterinary biomarkers industry faces limited direct substitutes because biomarkers provide objective biological information for early disease detection, prognosis, and treatment monitoring. Conventional diagnostic methods, including physical examinations, imaging techniques, microbiological culture, and routine laboratory tests, continue to play an important role in veterinary practice but often cannot deliver the same level of molecular or disease-specific insights. Consequently, biomarker-based diagnostics are increasingly being used alongside traditional diagnostic approaches to improve diagnostic accuracy and clinical decision-making.

The veterinary biomarkers sector is expanding in both developed and emerging regions, supported by rising pet ownership, increasing livestock production, and growing awareness of preventive animal healthcare. North America and Europe continue to lead the industry due to their well-established veterinary infrastructure, high expenditure on animal healthcare, and strong presence of diagnostic manufacturers.

Analyst Perspective

The veterinary biomarkers industry is expanding steadily, driven by the rising prevalence of chronic and infectious diseases in animals, increasing demand for early and accurate disease detection, and growing adoption of advanced veterinary diagnostics. Technological advancements in molecular diagnostics, immunoassays, genomics, proteomics, and liquid biopsy are expanding the identification and clinical application of disease-specific biomarkers. In addition, increasing veterinary research activities, growing use of biomarkers in drug development and treatment monitoring, and expanding adoption of point-of-care testing are further strengthening market growth, particularly across regions with established veterinary healthcare and research infrastructure.

Animal Insights

The companion animals segment led the market with the largest revenue share of 59.8% in 2025. Rising pet ownership, increasing expenditure on veterinary care, the growing prevalence of chronic diseases and cancer in companion animals, and the demand for early, non-invasive disease detection are driving the adoption of veterinary biomarkers. In addition, advancements in molecular diagnostics and increasing R&D investments are supporting segment growth. For instance, in 2025, IDEXX Laboratories launched IDEXX Cancer Dx, a blood-based diagnostic test that uses biomarker panels and multimodal bioanalytical techniques to detect canine lymphoma, thereby expanding access to biomarker-based cancer diagnostics in dogs. In addition, Cornell University College of Veterinary Medicine conducted a 2025–2026 study evaluating urinary cystatin B as an early biomarker of acute kidney injury in dogs, highlighting continued research into biomarkers for earlier disease detection and improved clinical outcomes.

The production animals segment is expected to grow at the fastest CAGR over the forecast period. Growth is driven by the high burden of infectious and metabolic diseases in livestock, the increasing need for early disease detection, the economic losses associated with livestock diseases, and the growing adoption of molecular and biomarker-based diagnostics for herd health management. For instance, in December 2025, the USDA Agricultural Research Service initiated a research project to develop improved diagnostic tools for theileriosis and babesiosis in livestock, including the use of parasite genome sequences to identify diagnostic targets and develop species-specific molecular and serological assays.

Product Insights

The biomarkers, kits & reagents segment led the market with the largest revenue share of 76.3% in 2025 and is anticipated to grow at the fastest CAGR during the forecast period. Segment growth is driven by the increasing prevalence of infectious and chronic diseases in animals, the growing demand for early and accurate diagnosis, and the wider adoption of immunoassay and molecular diagnostic technologies in veterinary practice. In addition, the availability of species-specific assays and the increasing use of biomarker testing for disease screening and monitoring are supporting demand for diagnostic kits and reagents. For instance, in 2025, DeepScan Diagnostics advanced its circulating cell-free DNA (cfDNA) biomarker testing for canine disease detection, supported by research evaluating cfDNA as a canine health biomarker and studies examining its application in neoplasia, lymphoma remission, splenic disease, and treatment-response monitoring. The company also presented multiple cfDNA studies at ESVONC 2025, highlighting the growing clinical application of molecular biomarkers for early disease detection and monitoring in dogs. Such developments are increasing the demand for specialized biomarker assays, kits, and associated reagents in veterinary diagnostics.

The instruments segment is anticipated to grow at a significant CAGR over the forecast period. Growth is driven by the increasing adoption of advanced veterinary diagnostic platforms, rising demand for rapid and accurate biomarker detection, and growing use of automated analyzers across veterinary hospitals, clinics, and diagnostic laboratories. Technological advancements in immunoassay, molecular diagnostic, and point-of-care platforms are enabling faster sample processing, improved analytical sensitivity, and accurate detection and quantification of disease-associated biomarkers. In addition, rising veterinary testing volumes, increasing adoption of point-of-care diagnostics, and growing investments in veterinary laboratory infrastructure are expected to drive demand for advanced diagnostic instruments over the forecast period.

Application Insights

The disease diagnostics segment led the market with the largest revenue share of over 48.9% in 2025. Segment growth is driven by the increasing emphasis on early disease detection and the growing adoption of rapid, biomarker-based, and molecular diagnostic testing. Increasing veterinary visits and demand for point-of-care testing are further supporting diagnostic applications. For instance, in March 2025, Antech launched trūRapid FOUR, an in-house canine vector-borne disease screening test that detects antibodies against Anaplasma, Ehrlichia, and Lyme C6, and heartworm antigen, using whole blood, serum, or plasma. The introduction of multi-disease screening solutions that enable rapid detection of disease-associated antibodies and antigens is strengthening the role of biomarkers in veterinary disease diagnostics.

The preclinical research segment is expected to grow at the fastest CAGR over the forecast period. Growth is driven by increasing R&D activities in veterinary drug development, expanding biomarker discovery programs, and growing use of molecular and genomic technologies to understand disease mechanisms and evaluate therapeutic response. Biomarkers are increasingly incorporated into research to support early disease detection, treatment response assessment, and the development of targeted therapies. For instance, the University of Minnesota College of Veterinary Medicine was conducting the COED study, which collects blood samples from dogs to develop a test for the early detection of canine osteosarcoma. Such research initiatives are expanding the identification and validation of novel biomarkers and supporting their application in veterinary preclinical and translational research.

Disease Type Insights

The inflammatory & infectious diseases segment led the market with the largest revenue share of 33.2% in 2025. The high burden of bacterial, viral, and parasitic infections in companion and production animals, increased disease surveillance, and the growing demand for rapid, early identification of pathogens and inflammatory responses are primarily driving the market growth. Biomarkers such as antigens, antibodies, acute-phase proteins, and inflammatory markers are increasingly used to support disease diagnosis and monitoring. For instance, in July 2025, ICAR-NIVEDI released three new diagnostic kits, Capripox Detect, FLUKEVEY, and CYSTISURE, for detecting capripox infections, bovine fasciolosis, and porcine cysticercosis, respectively. The expansion of disease-specific diagnostic tools, coupled with strengthened livestock surveillance programs, is supporting the adoption of biomarkers for the management of infectious and inflammatory diseases.

The oncology segment is expected to grow at the fastest CAGR over the forecast period. Growth is driven by the rising burden of cancer in companion animals, the increasing demand for early, non-invasive cancer detection, and the expanding adoption of liquid biopsy, genomic profiling, and tumor-specific biomarkers for diagnosis and treatment monitoring. According to the 2026 AAHA Oncology Guidelines, cancer affects approximately 50% of dogs and 30% of cats over 10 years of age, highlighting a substantial need for improved cancer diagnostics. The guidelines also identify liquid biopsy and precision medicine profiling as emerging approaches in veterinary oncology, using blood, urine, and tumor samples to detect biomarkers and characterize tumors. The growing cancer burden, coupled with advances in molecular diagnostics and precision oncology, is expected to accelerate the adoption of biomarkers in this segment.

End Use Insights

The veterinary hospitals & clinics segment led the market with the largest revenue share of 56.5% in 2025. The high volume of animal consultations, the increasing adoption of point-of-care diagnostics, the rising demand for rapid clinical decision-making, and the growing availability of advanced biomarker tests in veterinary practices are primarily driving segment growth. Hospitals and clinics increasingly use in-house diagnostic platforms to evaluate disease-associated biomarkers and obtain results during patient visits. For instance, in June 2025, IDEXX launched the Catalyst Cortisol Test, enabling veterinarians to quantitatively measure cortisol at the point of care to support the diagnosis and management of Addison’s and Cushing’s diseases in dogs. The test was scheduled for global rollout to an installed base of more than 75,000 Catalyst chemistry analyzers, reflecting the expanding infrastructure for in-clinic biomarker testing and supporting segment growth. 

To learn more about this report, Download Free Sample Report

The others segment is anticipated to grow at the fastest CAGR over the forecast period. The segment includes academic and research institutes, government veterinary laboratories, zoos, wildlife conservation centers, animal shelters, and other organizations involved in animal health research, surveillance, and diagnostics. Growth is driven by increasing veterinary biomarker research, expansion of animal disease surveillance programs, rising government funding for animal health research, and growing collaboration between academic institutions and diagnostic organizations. In addition, the increasing use of biomarkers in drug discovery and preclinical studies, zoonotic disease surveillance, wildlife disease monitoring, and the development and validation of novel veterinary diagnostics is driving demand across these end uses. The growing emphasis on One Health initiatives and the early identification of emerging animal diseases is expected to further accelerate the adoption of biomarker-based technologies across research and surveillance settings.

Regional Insights

North America dominated the global veterinary biomarkers market with the largest revenue share of 33.0% in 2025,driven by the strong presence of veterinary diagnostic companies, high adoption of advanced diagnostic technologies, increasing animal healthcare expenditure, and expanding research on biomarkers for early disease detection and treatment monitoring. The region also benefits from an established network of veterinary hospitals, diagnostic laboratories, and research institutions, supporting the adoption of molecular, immunoassay, and point-of-care biomarker testing. According to the 2025 AVMA Economic State of the Veterinary Profession report, veterinary services accounted for 78.5% of total revenue across U.S. veterinary practices in 2024, including laboratory testing, imaging, examinations, hospitalization, and other medical services. In companion animal-exclusive practices, veterinary services accounted for an even higher share of total revenue at 79.2%, highlighting strong utilization of clinical and diagnostic services that drive demand for veterinary biomarker testing in the region.

To learn more about this report, Download Free Sample Report

U.S. Veterinary Biomarkers Market Trends

The veterinary biomarkers market in the U.S. accounted for the largest market revenue share in North America in 2025, driven by high pet ownership, substantial veterinary care expenditure, advanced diagnostic infrastructure, and increasing adoption of molecular and biomarker-based tests for early disease detection and monitoring. The presence of leading animal health and veterinary diagnostic companies, coupled with growing research activities and demand for preventive care, further supports market growth. According to the American Pet Products Association (APPA), 95 million U.S. households owned at least one pet in 2025, while total U.S. pet industry expenditure reached USD 158 billion. The large pet population and significant spending on animal health create a strong environment for the adoption of advanced veterinary diagnostics and biomarker-based testing in the country.

Canada veterinary biomarkers marketis driven by growing investments in animal health research, expanding veterinary diagnostic infrastructure, increasing adoption of molecular and omics-based technologies, and strengthening animal disease surveillance programs. The country's large companion animal population and growing emphasis on early disease detection further support biomarker testing. In June 2025, the Governments of Canada and Saskatchewan announced USD 3.4 million in funding over four years to develop two research facilities at the University of Saskatchewan, including an Omics Resource Center at the Western College of Veterinary Medicine. The center is intended to expand genomics, proteomics, and metabolomics research capabilities, supporting advanced animal health research and the identification and analysis of disease-related biomarkers.

Europe Veterinary Biomarkers Market Trends

The veterinary biomarkers market in Europe is growing, driven by increasing adoption of advanced veterinary diagnostics, rising prevalence of chronic and infectious diseases in animals, and growing demand for early and accurate disease detection. The region benefits from well-established veterinary healthcare infrastructure, increasing expenditure on companion animal care, and strong research activities in animal health and life sciences. In addition, expanding use of molecular diagnostics, immunoassays, genomic technologies, and point-of-care testing, coupled with growing disease surveillance and One Health initiatives, is accelerating the integration of biomarkers into veterinary diagnosis, disease monitoring, and research across Europe.

The Germany veterinary biomarkers market held the significant share in Europe in 2025, fueled by the country's large companion animal population, established veterinary laboratory network, strong animal disease surveillance, and increasing adoption of molecular and serological diagnostics. Germany also benefits from extensive government-backed research and reference laboratory infrastructure for infectious diseases and zoonoses. In 2025, the Friedrich-Loeffler-Institut (FLI) authorized several new veterinary infectious-disease diagnostics, including assays for bluetongue virus, foot-and-mouth disease, and African swine fever, reflecting continued expansion of advanced animal disease testing. In addition, Germany had 33.4 million companion animals in 2025, including 15.7 million cats and 10.0 million dogs, creating a substantial population requiring disease screening and diagnostic services. These factors are supporting demand for biomarker-based testing across companion and production animals.

The veterinary biomarkers market in the UK is expected to grow at a significant CAGR over the forecast period. The market is driven by increasing investment in animal disease surveillance, strong veterinary research capabilities, and growing adoption of genomics and molecular diagnostics for pathogen detection and disease monitoring. The country's focus on biosecurity and One Health approaches is further encouraging advanced diagnostic research across livestock, companion animals, and wildlife. For instance, in May 2025, the UK government announced approximately USD 13.3 million in funding for the Genomics for Animal and Plant Disease Consortium (GAP-DC), led by the Animal and Plant Health Agency (APHA). The program uses advanced genome sequencing to detect, identify, and track pathogens across animal, plant, and aquatic environments. Such investment in genomic surveillance and pathogen characterization is expected to support the development and adoption of advanced veterinary biomarkers and molecular diagnostic technologies in the UK.

Asia Pacific Veterinary Biomarkers Market Trends

The veterinary biomarkers market in the Asia Pacific is expected to grow at the fastest CAGR over the forecast period, driven by the region’s large livestock base, intensification of commercial animal farming, recurring outbreaks of transboundary animal diseases, and increasing government focus on livestock productivity and biosecurity. Rapid development of organized dairy, poultry, and swine industries across China, India, and Southeast Asia is increasing the need for disease screening and herd-level health monitoring. In addition, government-led vaccination and disease eradication programs are driving greater demand for serological and molecular testing to assess infection, immunity, and disease prevalence. The expansion of domestic animal-health biotechnology industries and the increasing localization of veterinary diagnostic manufacturing are further improving the availability of biomarker-based tests across the region.

The China veterinary biomarkers marketis accelerating, driven by the modernization of veterinary diagnostic standards, rapid development of the domestic pet healthcare sector, and increasing need for sensitive and standardized testing for economically important animal diseases. Growing regulatory emphasis on diagnostic quality and the expansion of veterinary laboratory capabilities are further encouraging the use of molecular and serological biomarkers. For instance, in May 2025, China released the national standard GB/T 18646-2025 on diagnostic techniques for animal brucellosis, replacing the 2018 standard and taking effect in December 2025. In addition, China's Ministry of Agriculture and Rural Affairs reported 24 major animal diseases in December 2025, affecting approximately 103,035 animals, demonstrating the continued need for reliable disease detection and diagnostic technologies. These developments are supporting greater adoption of veterinary biomarker-based testing across China.

The veterinary biomarkers market in Japanis drivenby the increasing adoption of advanced veterinary diagnostics, growing research on disease-specific biomarkers, and rising demand for early detection and monitoring of chronic diseases in companion animals. Japan's strong capabilities in molecular biology, genomics, and veterinary research are supporting the development of biomarker-based approaches for oncology, renal disorders, infectious diseases, and other animal health conditions. In addition, the presence of specialized veterinary hospitals, university veterinary research centers, and diagnostic laboratories is facilitating the translation of novel biomarkers into clinical testing. The growing use of molecular and immunological techniques for disease characterization and treatment monitoring is expected to further support the adoption of veterinary biomarkers in Japan.

The India veterinary biomarkers marketis experiencing rapid growth, driven by expanding government investment in animal disease diagnostics, strengthening laboratory infrastructure, and increasing use of serological and molecular testing under national livestock disease-control programs. The growing emphasis on monitoring vaccination response and detecting economically important diseases is creating demand for antibodies, antigens, molecular markers, and other diagnostic biomarkers. According to the Department of Animal Husbandry and Dairying’s Annual Report 2024–25, 36,592 samples were analyzed during 2024 across virology, bacteriology, parasitology, pathology, and toxicology laboratories at the Central Disease Diagnostic Laboratory (IVRI). In addition, RT-PCR testing for Newcastle disease, avian influenza, African swine fever, and leptospirosis was initiated at the Northern Regional Disease Diagnostic Laboratory, demonstrating the expansion of molecular diagnostic capabilities supporting veterinary biomarker adoption in India.

Latin America Veterinary Biomarkers Market Trends

The veterinary biomarkers market in the Latin America is expected to grow significantly, due to the region’s large cattle, poultry, and swine industries and increasing need to minimize productivity losses associated with animal diseases. The expansion of export-oriented meat and dairy production is encouraging producers to strengthen herd health monitoring, disease certification, and diagnostic testing to meet international animal health and food safety requirements. In addition, recurring risks posed by transboundary and zoonotic diseases are increasing the need for rapid identification of infections across commercial farms. The modernization of livestock production systems, expansion of veterinary laboratory capacity, and increasing participation of Brazil, Mexico, and Argentina in animal health research are further supporting the adoption of veterinary biomarkers across the region.

The Brazil veterinary biomarkers market is experiencing robust growth, as increasing modernization of federal animal diagnostic laboratories, adoption of standardized molecular testing methods, and rising demand for disease-specific diagnostic kits strengthen the country’s veterinary testing capabilities. Brazil’s extensive livestock industry and strict sanitary requirements for animal production and trade are also increasing the need for reliable laboratory testing and disease monitoring. For instance, in July 2025, Brazil’s Ministry of Agriculture and Livestock (MAPA) initiated procurement of diagnostic kits and biological inputs for the Animal Diagnosis and Genetic Identification Unit at the Federal Agricultural Defense Laboratory in Recife (LFDA-PE). The procurement covers laboratory requirements for 2025 and 2026, demonstrating continued investment in veterinary diagnostic capacity and supporting demand for biomarker-based kits and reagents in Brazil.

Middle East & Africa Veterinary Biomarkers Market Trends

The veterinary biomarkers market in the Middle East & Africa is witnessing steady growth, driven by increasing focus on livestock health, rising demand for improved animal disease management, and gradual expansion of veterinary diagnostic capabilities. The region’s dependence on livestock for meat and dairy production is encouraging greater emphasis on maintaining animal health and productivity. In addition, growing government initiatives to strengthen veterinary services, increasing need to control zoonotic and transboundary animal diseases, and the development of animal health laboratories are supporting the use of biomarkers for disease detection and monitoring. Improving access to molecular and serological testing across emerging markets is further expected to support market growth over the forecast period.

The Saudi Arabia veterinary biomarkers market is rapidly growing, driven by the increasing digitalization of animal health management, the modernization of veterinary laboratories, and a growing emphasis on accurate disease testing for the country’s livestock population. Government efforts to strengthen laboratory quality standards and integrate advanced technologies into disease detection are creating a favorable environment for biomarker-based diagnostics. For instance, in August 2025, the Weqaa Center’s Jazan laboratory received ISO/IEC 17025 accreditation for veterinary testing, covering specialized tests for priority diseases including Rift Valley fever, peste des petits ruminants, foot-and-mouth disease, brucellosis, and toxoplasmosis. The center also established a 2025–2026 plan to expand laboratory accreditation in additional regions, strengthening the country’s capacity for reliable veterinary disease testing and supporting the adoption of veterinary biomarkers.

Key Veterinary Biomarkers Company Insights

The global market is fairly competitive. Key companies deploy strategic initiatives, such as product development, launches, and sales & marketing strategies to increase product awareness and regional expansions and partnerships to strengthen their market share. Market players are also involved in conducting clinical testing of their products, patent applications, and increasing product penetration.

Key Veterinary Biomarkers Companies

The following key companies have been profiled for this study on the veterinary biomarkers market.

• Zoetis

• Virbac

• Life Diagnostics

• ACUVET BIOTECH

• Merck

• IDEXX Laboratories, Inc.

• MI:RNA Diagnostics Ltd.

• Mercodia AB

• Antech Diagnostics, Inc.

• Avacta Animal Health Limited

Recent Developments

• In January 2026, IDEXX Laboratories announced the expansion of its Cancer Dx Panel to detect canine mast cell tumors, with availability planned for mid-2026 in North America. In addition to lymphoma detection, the expanded panel is expected to address more than one-third of canine cancer cases and uses proprietary cancer biomarkers for screening.

• In August 2025, Carus Animal Health launched GIQuest, a clinically validated, patient-side fecal calprotectin lateral-flow test for dogs and cats. Fecal calprotectin is an inflammatory biomarker associated with neutrophilic infiltration of the intestinal mucosa, enabling non-invasive investigation and monitoring of gastrointestinal inflammation.

• In August 2025, POP launched a 90-day canine health study with Innovative Pet Lab and Embark Veterinary, enrolling up to 100 dogs and combining gut biomarker test kits, DNA testing, nutrition interventions, and activity data to investigate canine immunity and long-term health. 

Global Veterinary Biomarkers Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global veterinary biomarkers market report based on animal, product, application, disease type, end use, and region:

• Animal Outlook (Revenue, USD Million, 2021 - 2033)

  • Companion Animals

    • Dogs

    • Cats

    • Horses

    • Others

  • Production Animals

    • Cattle

    • Pigs

    • Poultry

    • Others

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Biomarkers, Kits & Reagents

  • Instruments

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Disease Diagnostics

  • Preclinical Research

  • Others

• Disease Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Inflammatory & Infectious Diseases

  • Cardiovascular Diseases

  • Musculoskeletal Diseases

  • Oncology

  • Others

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Veterinary Diagnostic Laboratories

  • Veterinary Hospitals & Clinics

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033) 

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • UAE

    • Saudi Arabia

    • Kuwait

    • Qatar

    • Oman

Research Methodology

The veterinary biomarkers market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each veterinary biomarkers segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations